{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/109503"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/109503","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Fluid and blood pressure management in maintenance hemodialysis patients","abstract":"While the majority of the nephrology community would agree that the ideal way to manage the care of a patient on dialysis is through proper volume control strategies, our guidelines and protocols do not reflect these beliefs. The Kidney Disease Outcomes Quality Initiative (KDOQI) has guidelines for treating hypertension in hemodialysis (HD) patients, but it does not provide specific recommendations for managing polypharmacy and deprescribing anti-hypertensive medications. When patients transition from non-dialysis CKD to chronic HD therapy, the requirement for anti-hypertensive medications may change due to the removal of extracellular fluid by ultrafiltration and other factors. Because most blood pressure medications are vasodilators or impact other components of cardiovascular function, they may prevent the normal physiological response to changes in volume during dialysis, leading to intra- or inter-dialytic hypotension, post dialysis fatigue,[1, 2] and a reduced quality of life for patients.[3] Indeed, hypotensive symptoms may occur in more than 20%-50% of dialysis sessions.[1, 4] These symptoms not only make the treatment ineffective or harmful, but also creates a sense of fear in the patients, which makes them resist proposed increases in ultrafiltration volume to achieve or maintain dry weight. Several studies have shown that patients who experience frequent hypotensive events during dialysis have poorer survival.[5, 6] Ultimately, avoiding or minimizing pharmacologic control of blood pressure may facilitate fluid removal and accurate dry weight achievement, which in turn may prevent the myocardial remodeling that is often seen in dialysis patients.[7, 8] This body of work aims to demonstrate the need for and potential eligibility criteria for a comprehensive antihypertensive medication deprescribing protocol in the maintenance hemodialysis population.","abstract_html":"While the majority of the nephrology community would agree that the ideal way to manage the care of a patient on dialysis is through proper volume control strategies, our guidelines and protocols do not reflect these beliefs. The Kidney Disease Outcomes Quality Initiative (KDOQI) has guidelines for treating hypertension in hemodialysis (HD) patients, but it does not provide specific recommendations for managing polypharmacy and deprescribing anti-hypertensive medications. When patients transition from non-dialysis CKD to chronic HD therapy, the requirement for anti-hypertensive medications may change due to the removal of extracellular fluid by ultrafiltration and other factors. Because most blood pressure medications are vasodilators or impact other components of cardiovascular function, they may prevent the normal physiological response to changes in volume during dialysis, leading to intra- or inter-dialytic hypotension, post dialysis fatigue,[1, 2] and a reduced quality of life for patients.[3] Indeed, hypotensive symptoms may occur in more than 20%-50% of dialysis sessions.[1, 4] These symptoms not only make the treatment ineffective or harmful, but also creates a sense of fear in the patients, which makes them resist proposed increases in ultrafiltration volume to achieve or maintain dry weight. Several studies have shown that patients who experience frequent hypotensive events during dialysis have poorer survival.[5, 6] Ultimately, avoiding or minimizing pharmacologic control of blood pressure may facilitate fluid removal and accurate dry weight achievement, which in turn may prevent the myocardial remodeling that is often seen in dialysis patients.[7, 8] This body of work aims to demonstrate the need for and potential eligibility criteria for a comprehensive antihypertensive medication deprescribing protocol in the maintenance hemodialysis population.","abstract_has_math":false,"creators":["Derk, Gwendolyn"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Community Health","degree_department":null,"school":null,"contributors":["Wilund, Ken","Pai, Amy","Andrade, Flavia","An, Roupeng"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-03-05T21:40:47Z","date_published":"2021-03-05T21:40:47Z","updated_at":"2026-07-22T22:24:50Z","subjects":["Hemodialysis End-Stage Kidney Disease Chronic Kidney Disease Anti Hypertensive Medications Dry Weight Fluid Overload"],"languages":["en"],"rights":["Copyright 2020 Gwendolyn Derk"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/109503","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Wilund, Ken","Pai, Amy","Andrade, Flavia","An, Roupeng"]},{"key":"dc:creator","label":"Author","values":["Derk, Gwendolyn"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2021-03-05T21:40:47Z","2023-03-05T21:43:00Z","2020-12-01","2020-12"]},{"key":"dc:type","label":"Dc Type","values":["text","Thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Community Health"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Hemodialysis End-Stage Kidney Disease Chronic Kidney Disease Anti Hypertensive Medications Dry Weight Fluid Overload"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2020 Gwendolyn Derk"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/109503"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["While the majority of the nephrology community would agree that the ideal way to manage the care of a patient on dialysis is through proper volume control strategies, our guidelines and protocols do not reflect these beliefs. The Kidney Disease Outcomes Quality Initiative (KDOQI) has guidelines for treating hypertension in hemodialysis (HD) patients, but it does not provide specific recommendations for managing polypharmacy and deprescribing anti-hypertensive medications. When patients transition from non-dialysis CKD to chronic HD therapy, the requirement for anti-hypertensive medications may change due to the removal of extracellular fluid by ultrafiltration and other factors. Because most blood pressure medications are vasodilators or impact other components of cardiovascular function, they may prevent the normal physiological response to changes in volume during dialysis, leading to intra- or inter-dialytic hypotension, post dialysis fatigue,[1, 2] and a reduced quality of life for patients.[3] Indeed, hypotensive symptoms may occur in more than 20%-50% of dialysis sessions.[1, 4] These symptoms not only make the treatment ineffective or harmful, but also creates a sense of fear in the patients, which makes them resist proposed increases in ultrafiltration volume to achieve or maintain dry weight. Several studies have shown that patients who experience frequent hypotensive events during dialysis have poorer survival.[5, 6] Ultimately, avoiding or minimizing pharmacologic control of blood pressure may facilitate fluid removal and accurate dry weight achievement, which in turn may prevent the myocardial remodeling that is often seen in dialysis patients.[7, 8] This body of work aims to demonstrate the need for and potential eligibility criteria for a comprehensive antihypertensive medication deprescribing protocol in the maintenance hemodialysis population.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2022-12-01","The student, Gwendolyn Derk, accepted the attached license on 2020-11-21 at 17:11.","The student, Gwendolyn Derk, submitted this Dissertation for approval on 2020-11-21 at 17:30.","This Dissertation was approved for publication on 2020-12-01 at 14:23.","DSpace SAF Submission Ingestion Package generated from Vireo submission #15930 on 2021-03-04 at 16:19:46","Made available in DSpace on 2021-03-05T21:40:47Z (GMT). No. of bitstreams: 3 DERK-DISSERTATION-2020.pdf: 2059228 bytes, checksum: f18b4010b6db0986e4f84f303be51b3d (MD5) LICENSE.txt: 4211 bytes, checksum: a7cc132200a20416fcd684cad9b26557 (MD5) PROQUEST_LICENSE.txt: 4557 bytes, checksum: 62d6e33237c9c83684d2f009497a7ca2 (MD5) Previous issue date: 2020-12-01","Embargo set by: Seth Robbins for item 117207 Lift date: 2023-03-05T21:40:52Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 117207 Lift date: 2023-03-05T21:43:00Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Fluid and blood pressure management in maintenance hemodialysis patients"]}]}],"canonical_facts":{"dc:contributor":["Wilund, Ken","Pai, Amy","Andrade, Flavia","An, Roupeng"],"dc:creator":["Derk, Gwendolyn"],"dc:date":["2021-03-05T21:40:47Z","2023-03-05T21:43:00Z","2020-12-01","2020-12"],"dc:description":["While the majority of the nephrology community would agree that the ideal way to manage the care of a patient on dialysis is through proper volume control strategies, our guidelines and protocols do not reflect these beliefs. The Kidney Disease Outcomes Quality Initiative (KDOQI) has guidelines for treating hypertension in hemodialysis (HD) patients, but it does not provide specific recommendations for managing polypharmacy and deprescribing anti-hypertensive medications. When patients transition from non-dialysis CKD to chronic HD therapy, the requirement for anti-hypertensive medications may change due to the removal of extracellular fluid by ultrafiltration and other factors. Because most blood pressure medications are vasodilators or impact other components of cardiovascular function, they may prevent the normal physiological response to changes in volume during dialysis, leading to intra- or inter-dialytic hypotension, post dialysis fatigue,[1, 2] and a reduced quality of life for patients.[3] Indeed, hypotensive symptoms may occur in more than 20%-50% of dialysis sessions.[1, 4] These symptoms not only make the treatment ineffective or harmful, but also creates a sense of fear in the patients, which makes them resist proposed increases in ultrafiltration volume to achieve or maintain dry weight. Several studies have shown that patients who experience frequent hypotensive events during dialysis have poorer survival.[5, 6] Ultimately, avoiding or minimizing pharmacologic control of blood pressure may facilitate fluid removal and accurate dry weight achievement, which in turn may prevent the myocardial remodeling that is often seen in dialysis patients.[7, 8] This body of work aims to demonstrate the need for and potential eligibility criteria for a comprehensive antihypertensive medication deprescribing protocol in the maintenance hemodialysis population.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2022-12-01","The student, Gwendolyn Derk, accepted the attached license on 2020-11-21 at 17:11.","The student, Gwendolyn Derk, submitted this Dissertation for approval on 2020-11-21 at 17:30.","This Dissertation was approved for publication on 2020-12-01 at 14:23.","DSpace SAF Submission Ingestion Package generated from Vireo submission #15930 on 2021-03-04 at 16:19:46","Made available in DSpace on 2021-03-05T21:40:47Z (GMT). No. of bitstreams: 3 DERK-DISSERTATION-2020.pdf: 2059228 bytes, checksum: f18b4010b6db0986e4f84f303be51b3d (MD5) LICENSE.txt: 4211 bytes, checksum: a7cc132200a20416fcd684cad9b26557 (MD5) PROQUEST_LICENSE.txt: 4557 bytes, checksum: 62d6e33237c9c83684d2f009497a7ca2 (MD5) Previous issue date: 2020-12-01","Embargo set by: Seth Robbins for item 117207 Lift date: 2023-03-05T21:40:52Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 117207 Lift date: 2023-03-05T21:43:00Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only"],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/109503"],"dc:language":["en"],"dc:rights":["Copyright 2020 Gwendolyn Derk"],"dc:subject":["Hemodialysis End-Stage Kidney Disease Chronic Kidney Disease Anti Hypertensive Medications Dry Weight Fluid Overload"],"dc:title":["Fluid and blood pressure management in maintenance hemodialysis patients"],"dc:type":["text","Thesis"],"thesis:degree_discipline":["Community Health"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:50Z"}